Akeso ivonescimab outperforms AstraZeneca Imfinzi in phase three cancer trial
Chinese biopharmaceutical Akeso reported that its ivonescimab drug extended survival longer than AstraZeneca's Imfinzi in a late-stage biliary cancer trial, validating its multibillion-dollar licensing deal with Summit Therapeutics and signaling growing global competitiveness for China's biotech sector.
Akeso announced Wednesday that its immunotherapy ivonescimab outperformed AstraZeneca's Imfinzi in a head-to-head phase three trial for advanced biliary tract cancer. The Zhongshan-headquartered company disclosed the top-line results in a Hong Kong stock exchange filing released a day before its interim financial results.
The study evaluated 682 patients receiving either ivonescimab combined with chemotherapy or AstraZeneca's durvalumab alongside chemotherapy. Patients treated with the Akeso regimen lived longer than those on the AstraZeneca protocol, the company stated.
Akeso has not yet released the exact survival metrics from the study. The biopharmaceutical firm is expected to present the detailed clinical data at an upcoming medical conference.
This clinical victory carries significant commercial implications for Akeso and its international partners. Ivonescimab was previously licensed to US-based Summit Therapeutics in a multibillion-dollar agreement. The robust late-stage data now provides stronger validation for that massive capital deployment and the asset's global revenue potential.
The positive phase three outcome in gastrointestinal tumours expands the commercial footprint of the drug. Xia Yu, founder and chief executive of Akeso, noted that the success potentially opens the door for the drug to be used in a "broader range of solid tumours".
The trial highlights the escalating ambitions of China's biopharma sector to compete globally against established Western incumbents like AstraZeneca. Biliary tract cancer is a highly lethal disease, with a Nature study citing a five-year survival rate of less than 5 per cent. Delivering a survival benefit in such a difficult indication creates substantial pricing and market share opportunities.
This biliary cancer trial follows earlier clinical indications that ivonescimab shows promise in treating certain lung cancers. Continued success across multiple tumour types would significantly expand the drug's total addressable market. It also reinforces the strategic rationale for Western pharmaceutical firms seeking to license innovative assets from Chinese developers.
The timing of the announcement coincides with the company's broader financial reporting cycle. Management released the clinical update via the stock exchange a day ahead of its scheduled interim results. Investors will be watching closely to see how the firm frames the financial impact of this expanded clinical profile during the upcoming earnings briefing.
